MLXIPL and metabolic dysfunction-associated steatotic liver disease: In chronic diet-induced obesity and NAFLD, hyperglycemia, hyperinsulinemia, and hyperlipidemia are observed, accompanied by enhanced de novo lipogenesis and cholesterogenesis through the activation of hepatic transcription factors, including sterol-regulatory element-binding transcription factor 1 (SREBP-1), SREBP-2, and MLX-interacting protein-like (MLXIPL, also known as carbohydrate-responsive element-binding protein) [5,6].